

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|  |   |    |   |                          |                        |
|--|---|----|---|--------------------------|------------------------|
| <p>Substitute for form 1449A/PTO</p> <p><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b></p> <p><i>(Use as many sheets as necessary)</i></p> |   |    |   | <b>Complete if Known</b> |                        |
|  |   |    |   | Application Number       | 10/581,340-Conf. #8446 |
|  |   |    |   | Filing Date              | June 2, 2006           |
|  |   |    |   | First Named Inventor     | David S. GARVEY        |
|  |   |    |   | Art Unit                 | 1626                   |
|  |   |    |   | Examiner Name            | J. M. Nolan            |
|  |   |    |   | Attorney Docket Number   | 0102258.00368US2       |
| Sheet  | 1 | of | 2 |                          |                        |

[illegible][illegible]

|                       |  |                    |  |
|-----------------------|--|--------------------|--|
| Examiner<br>Signature |  | Date<br>Considered |  |
|-----------------------|--|--------------------|--|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

|  |   |    |   |                          |                        |
|--|---|----|---|--------------------------|------------------------|
| Substitute for form 1449/PTO<br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br><i>(Use as many sheets as necessary)</i> |   |    |   | <b>Complete if Known</b> |                        |
|  |   |    |   | Application Number       | 10/581,340-Conf. #8446 |
|  |   |    |   | Filing Date              | June 2, 2006           |
|  |   |    |   | First Named Inventor     | David S. GARVEY        |
|  |   |    |   | Art Unit                 | 1626                   |
|  |   |    |   | Examiner Name            | J. M. Nolan            |
| Sheet  | 2 | of | 2 | Attorney Docket Number   | 0102258.00368US2       |

| NON PATENT LITERATURE DOCUMENTS |                       |   |                |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials*              | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T <sup>2</sup> |
|                                 | CA                    | Bauer, et al. "Nitric Oxide Donors: Biochemical Pharmacology and Therapeutics." Advances in Pharmacology, (1995), pages 361-381.  |                |
|                                 | CB                    | European Search Report, based on PCT/US04/041069, mailed September 30, 2008.  |                |
|                                 | CC                    | Hanson, et al. "Nitric Oxide Donors: A Continuing Opportunity in Drug Design." Advances in Pharmacology (1995), pages 383-398.  |                |
|                                 | CD                    | Ignarro, et al. "Nitric Oxide Donors and Cardiovascular Agents Modulating the Bioactivity of Nitric Oxide." Circulation Research, (2002) Vol. 90, pages 21-28.  |                |
|                                 | CE                    | International Search Report based on PCT/US04/041069, mailed August 23, 2005.   |                |
|                                 | CF                    | Lopatin, et al. "Pyruvamides. 3. Involvement of the Amide Group in Carbinolamine Formation, gem-Diamine Formation, and Transimination." J. Amer. Chem. Soc., (1979), Vol. 101(4), pages 960-969.  |                |
|                                 |                       |   |                |
|                                 |                       |   |                |
|                                 |                       |   |                |
|                                 |                       |   |                |

|                    |  |                 |  |
|--------------------|--|-----------------|--|
| Examiner Signature |  | Date Considered |  |
|--------------------|--|-----------------|--|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.